Daphne Quimi Buys Shares of IPSC $IPSC

Key Points

  • Daphne Quimi bought 74,000 shares of Century Therapeutics, Inc. ($IPSC).
  • $IPSC last traded around $2.25.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Daphne Quimi, insider at Century Therapeutics, Inc. ($IPSC), bought 74,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Century Therapeutics, Inc. Stock Up 11.1%

Shares of Century Therapeutics, Inc. ($IPSC) traded around $2.25 on Saturday, up 11.1% for the day.

Last price$2.25
Market cap$369.73M
Forward P/E-4.53
Beta1.60
52-week low$0.43
52-week high$3.04
50-day MA$2.16
200-day MA$1.91
Current ratio8.28
Quick ratio8.04
Debt-to-equity0.17

Century Therapeutics, Inc. Earnings

EPS (ttm)-$0.94
Revenue (ttm)
Net margin0%
Return on equity-49.65%
Next earningsNov 12, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$4.75
High target$8
Low target$2
Analysts covering4

About Century Therapeutics, Inc.

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersPhiladelphia, PA
CEODr. Brent Pfeiffenberger M.B.A., Pharm.D.
Employees78

Get Century Therapeutics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $IPSC, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.